The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | AMPLIFY trial: how prognostic mutations impact outcomes with acalabrutinib-venetoclax in CLL
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses an exploratory analysis of the Phase III AMPLIFY trial (NCT03836261) evaluating how key prognostic mutations impact outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy in chronic lymphocytic leukemia (CLL). Prof. Ghia highlights consistent progression-free survival (PFS) benefits across genetic subgroups and the potential added value of obinutuzumab in overcoming higher-risk features. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
